Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Ting-Ting LiuKai-Xia YangJing YuYing-Ya CaoJian-Song RenJia-Jie HaoBei-Qing PanSai MaLi-Yan YangYan CaiMing-Rong WangYu ZhangPublished in: Journal of molecular medicine (Berlin, Germany) (2018)
PLK1 potentiates both mTORC1 and mTORC2 activities in ESCC cells. PLK1 expression positively correlated with mTOR activity in a subset of ESCC. Co-targeting of PLK1 and mTOR produced stronger antitumor effects partially due to synergistic inhibition of AKT, 4E-BP1 and S6 through cooperatively blocking mTORC2 and mTORC1 cascades. Combination targeting of PLK1 and mTOR may be a novel and promising therapeutic strategy for ESCC treatment.